deaths from glp-1 medications found to reduce deaths, amputations and hospitalisations in PAD and type 2 diabetes patients Glucagon-Like Peptide 1 Receptor Agonist

OB, olfactory bulb

Zhong J, Chen H, Liu Q, Zhou S, Liu Z, Xiao Y

Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is FDA-approved along with increased physical activity and a reduced-calorie diet for chronic weight management in adults with a starting body mass index (BMI) of: 30 kg/m^2 or higher (obesity) 27 kg/m^2 or higher (overweight) with at least one weight-related condition such as high cholesterol, high blood pressure (hypertension), type 2 diabetes, heart disease, or obstructive sleep apnea

Should patients expect benefits from offlabel uses

Always consult your doctor or medical care provider if you are considering any kind of treatment for diabetes and/or weight loss

Your provider may recommend checking your blood glucose more frequently for several days or adjusting your next dose timing to maintain therapeutic continuity